Related Experiment Video

Updated: Feb 21, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib

Konstantin Byrgazov1, Chantal Blanche Lucini1, Peter Valent2

  • 1Children's Cancer Research Institute; Vienna, Austria.

Haematologica
|October 7, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Experiment Videos

Last Updated: Feb 21, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

Articles linked to this work by shared authors, journal, and citation graph.

From fatal disease to functional cure: 25 years of tyrosine kinase inhibition in chronic myeloid leukemia.

Leukemia·2026

Development of mirror-image monobodies targeting the oncogenic BCR::ABL1 kinase.

Nature communications·2024

Cytosolic delivery of monobodies using the bacterial type III secretion system inhibits oncogenic BCR: ABL1 signaling.

Cell communication and signaling : CCS·2024

BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.

Blood·2024

Improving the pharmacokinetics, biodistribution and plasma stability of monobodies.

Frontiers in pharmacology·2024

Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl.

RSC chemical biology·2022

Genetic thrombophilia in cancer-associated thrombosis: the fly plowing with the ox or an old player's new role?

Haematologica·2026

From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".

Haematologica·2026

Learning from relapse: how MajesTEC-1 immune profiling points the way to next-generation bispecific strategies.

Haematologica·2026

Making remissions last: the promise of maintenance in primary central nervous system lymphoma.

Haematologica·2026

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Haematologica·2026

The many faces (and phenotypes) of BCR::ABL1-driven acute leukemia.

Haematologica·2026

Overcoming Resistance to Immune Checkpoint Blockade: Mechanistic Insights and Emerging Therapeutic Directions.

Iranian journal of immunology : IJI·2026

Cooperative Suppression of Ovarian Cancer Growth by 1,25-Dihydroxyvitamin D3 and Sodium Selenite Mediated Through SEPP1 Induction.

Cancer medicine·2026

The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review.

Cancer medicine·2026

Steven-Johnson Syndrome and Toxic Epidermal Necrolysis in a Patient Treated With Cabozantinib: A Case Report of a Fatal Adverse Reaction.

Asia-Pacific journal of clinical oncology·2026

Durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis: A case report.

Medicine·2026

Delineating SWI/SNF gene and subtype expression in cancer.

Epigenetics & chromatin·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us